INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINE
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
PURPOSE: We evaluated the incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease. We also assessed the predictive role of bone turnover markers determined at baseline. MATERIALS AND METHODS: A total of 112 patients were consecutively enrolled in our study from July 1990 to July 1998 and followed until death or the last followup. Bone pain, disease extent in bone, serum prostate specific antigen, hemoglobin, and a panel of bone formation and resorption markers were assessed at baseline before any second line treatment. RESULTS: Skeletal complications in 34 patients (30.3%, estimated yearly incidence 12.3%) involved vertebral deformity or collapse requiring spinal orthosis in 20 (17.9%), spinal cord compression in 7 (6.2%), pathological bone fracture in 10 (8.9%), symptomatic hypercalcemia in 1 (0.9%) and symptomatic hypocalcemia in 1 (0.9%). Median time to the evidence of the initial skeletal complication was 9.5 months. These adverse events did not influence overall survival. At baseline patients with eventual skeletal complications had greater bone pain (p = 0.02), a heavier tumor load in bone (p = 0.005), lower performance status (p = 0.05), and higher serum alkaline phosphatase (p <0.02) and urinary deoxypyridoline (p <0.05) than their counterparts. Multivariate analysis revealed that only urinary deoxypyridinoline was independently associated with the onset of these events (p <0.02). The scatterplot of urinary deoxypyridinoline values in patients with and without skeletal complications enabled us to detect a cutoff of 38 pM./mM. for predicting 51% of skeletal events with only an 8% false-positive rate. CONCLUSIONS: Skeletal complications are common in patients with prostate cancer and hormone refractory disease. Bone loss is the major cause of onset. Baseline deoxypyridinoline at the cutoff point noted had moderate sensitivity but high specificity for predicting these adverse skeletal events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common complication of prostate cancer is metastasis to the bone tissue, which occurs in about 10% of patients with primary disease and 80% of patients with advanced, late-stage disease (Berruti et al., 2000; Bubendorf et al., 2000).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Berruti et al., 2000
Citations
Cites
Nonparametric Statistics for the Behavioral Sciences
Guitton, H., & Siegel, S. (1958) · Revue économique · doi:10.2307/3498751 · Cited by 35,245
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Skeletal complications of malignancy
Coleman, R. E. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g · Cited by 1,502
A computer program for comparing K samples with right-censored data
Lee, E. T., & Desu, M. M. (1972) · Computer Programs in Biomedicine · doi:10.1016/0010-468x(72)90019-0 · Cited by 705
Hanson, D. A., Weis, M. A. E., Bollen, A.-M., Maslan, S. L., Singer, F. R., & Dr. Eyre, D. R. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650071119 · Cited by 656
Risteli, J., Elomaa, I., Niemi, S., Novamo, A., & Risteli, L. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.4.635 · Cited by 622
Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen
Melkko, J., Niemi, S., Risteli, L., & Risteli, J. (1990) · Clinical Chemistry · doi:10.1093/clinchem/36.7.1328 · Cited by 513
Guise, T. A., & Mundy, G. R. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0323 · Cited by 472
Molecular aspects of tumor cell invasion and metastasis
Aznavoorian, S. A., Murphy, A. N., Stetler‐Stevenson, W. G., & Liotta, L. A. (1993) · Cancer · doi:10.1002/1097-0142(19930215)71:4<1309::aid-cncr2820710423>3.0.co;2-m · Cited by 459
PROGRESSIVE OSTEOPOROSIS DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER
DANIELL, H. W., DUNN, S. R., FERGUSON, D. W., LOMAS, G., NIAZI, Z., & STRATTE, P. T. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)68000-7 · Cited by 452
Cited by
Items 101–200 of 213
Zhan, Y., Zhang, G., Li, M., & Zhou, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.633833 · Cited by 18
Wymenga, L. F. A., Groenier, K. H., Schuurman, J., Boomsma, J. H. B., Elferink, R. O., & Mensink, H. J. A. (2001) · British Journal of Urology · doi:10.1046/j.1464-410x.2001.02274.x · Cited by 18
“Urinary DPD may provide a useful marker to supplement ALP and PSA in evaluating bone scan results and the response to hormonal therapy [11, 12 ].”
BackgroundRodrigues, P. R. T., Hering, F., Bruna, P., Meller, A. E., & Afonso, Y. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2006.01721.x · Cited by 18
Bone-Directed Treatments for Prostate Cancer
Fred Saad, C. (2006) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2006.03.011 · Cited by 18
Markers of bone metabolism in prostate cancer
Smith, M. R. (2006) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(06)80006-x · Cited by 17
Targeted therapy in prostate cancer
Corcoran, N. M., & Gleave, M. E. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.04030.x · Cited by 16
Barrett, J. M., Rovedo, M. A., Tajuddin, A. M., Jilling, T., Macoska, J. A., MacDonald, J., Mangold, K. A., & Kaul, K. L. (2005) · The Prostate · doi:10.1002/pros.20370 · Cited by 16
Morgans, A. K., & Smith, M. R. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.07.009 · Cited by 20
Lipton, A. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181deb9e5 · Cited by 15
“An Italian study estimated a 30% overall incidence and 12% yearly incidence of skeletal complications in patients with bone metastatic prostate cancer.(73) Baseline characteristics associated with the development of skeletal complications included greater bone pain, heavier tumor load in bone, lower performance status…”
BackgroundVelde, N. V., Wu, E. Q., Guo, A. X., Lü, M., Yu, A. P., Sharma, H., Liu, J., Fan, C. P. S., & Shi, L. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.49 · Cited by 15
“Patients with hormone-refractory metastatic prostate cancer in particular are at a high risk of developing SREs”
BackgroundWong, K., Ma, W., Wong, C., Wong, M., Tsang, C., Tsu, H., Ho, K. F., & Yiu, M. (2015) · Hong Kong Medical Journal · doi:10.12809/hkmj144449 · Cited by 19
Advances in the use of bisphosphonates in the prostate cancer setting
Coxon, J. P., Oades, G. M., Colston, K. W., & Kirby, R. S. (2004) · Prostate Cancer and Prostatic Diseases · doi:10.1038/sj.pcan.4500705 · Cited by 15
Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma
Francini, G., Petrioli, R., Gonnelli, S., Correale, P., Pozzessere, D., Marsili, S., Montagnani, A., Lucani, B., Rossi, S., Monaco, R. D., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1468::aid-cncr1471>3.0.co;2-s · Cited by 15
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Management of metastatic disease of the appendicular skeleton
Ashford, R. U., Pendlebury, S. C., & Stalley, P. (2006) · Current Orthopaedics · doi:10.1016/j.cuor.2006.03.005 · Cited by 14
Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease
Dawson, N. A. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.5.705 · Cited by 14
“[57] in a prospective study of 112 men with hormone refractory disease and bone metastases followed until death, or last follow-up, documented skeletal complications in 30% of men, with an estimated yearly incidence of 12% [57].”
BackgroundBone metastases in prostate cancer: a targeted approach
Storey, J. A., & Torti, F. M. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32805e8787 · Cited by 13
Management of Metastatic Bone Disease and Hypercalcemia of Malignancy
Lipton, A. (2003) · American Journal of Cancer · doi:10.2165/00024669-200302060-00004 · Cited by 13
Bornemann, R., Pflugmacher, R., Frey, S. P., Roessler, P. P., Rommelspacher, Y., Wilhelm, K., Sander, K., Wirtz, D. C., & Grötz, S. (2016) · Technology and Health Care · doi:10.3233/thc-161160 · Cited by 12
“Spinal metastasis causing vertebral fractures compromises structural integrity and may lead to instabilities, neurological dysfunctions and an increased risk of further vertebral fractures [4–7].”
BackgroundHoff, B. A., Toole, M., Yablon, C. M., Ross, B. D., Luker, G. D., Poznak, C. H. V., & Galbán, C. J. (2015) · Tomography · doi:10.18383/j.tom.2015.00154 · Cited by 12
“Biochemical markers such as serum alkaline phosphatase and urinary deoxypyridoline have shown some promise for predicting pathological fractures (14).”
BackgroundClodronate for treatment of bone metastases in hormone refractory prostate cancer
Hering, F., Rodrigues, P. R. T., & Lipay, M. A. S. (2003) · International braz j urol · doi:10.1590/s1677-55382003000300006 · Cited by 12
“A direct action over the tumor was also described, inhibiting angiogenesis and promoting the apoptosis of cancerous cells, in addition to inhibiting metalloproteases and cytokines (1,7-9,13).”
BackgroundBisphosphonates: their evolving role in the management of prostate cancer-related bone disease
Dawson, N. A. (2002) · Current Opinion in Urology · doi:10.1097/00042307-200209000-00008 · Cited by 12
Farolfi, A., Ferrario, C., Aquilina, M., Cecconetto, L., Tartaglia, A., Ibrahim, T., Serra, L., Oboldi, D., Nizzoli, M., & Rocca, A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3326 · Cited by 11
“In such patients, hypocalcemia is typically mild and clinical signs are rare (affecting ~0.9% of patients) (4); however, cases of severe hypocalcemia have occasionally been reported (5-7).”
InfluentialWu, J., Lin, L., He, J., Liang, H., & Li, J. (2016) · Medicine · doi:10.1097/md.0000000000002789 · Cited by 11
“Skeletal-related events (SREs) are the major factors underlying morbidity in PCa and result in bone pain and deterioration of QOL.(17) A previous study showed that RT improved motor function in oligometastic patients with spinal cord compression.”
BackgroundInfluentialOsteoclast-targeted therapy for prostate cancer
Smith, M. R. (2004) · Current Treatment Options in Oncology · doi:10.1007/s11864-004-0027-1 · Cited by 11
“Markers of osteoclast activity predict independently the risk for subsequent skeletal complications, suggesting that cancer-mediated osteoclast activation not only accompanies bone metastases but also contributes to the clinical complications of metastatic disease [ 5 ].”
BackgroundRadioisotopic treatment of bone pain from metastatic prostate cancer
Sartor, O. A. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0119-2 · Cited by 11
Chappard, D., Mabilleau, G., Masson, C., Tahla, A., & Legrand, É. (2018) · Morphologie · doi:10.1016/j.morpho.2018.02.002 · Cited by 10
Serum alkaline phosphatase and 30-day mortality after surgery for spinal metastatic disease
Karhade, A. V., Thio, Q. C. B. S., Ogink, P. T., & Schwab, J. H. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2947-9 · Cited by 10
Role of bisphosphonates in prostate cancer bone metastases
Guise, T. A., & Chirgwin, J. M. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00347-6 · Cited by 10
Parajuli, K. R., Jung, Y., & Taichman, R. S. (2024) · Oncology Reports · doi:10.3892/or.2024.8698 · Cited by 9
Refractory hypocalcaemia complicating metastatic prostatic carcinoma
Rizzo, C., Vella, S., & Cachia, M. J. (2015) · BMJ Case Reports · doi:10.1136/bcr-2015-210003 · Cited by 9
The role of bisphosphonates in the management of prostate cancer
Fred Saad, C. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0023-7 · Cited by 9
“Levels of biochemical markers of osteolysis typically correlate with the extent of bone metastases in patients with prostate cancer [ 15 ], and these levels significantly correlate not only with pain levels and the risk of skeletal morbidity [15,16] but also with the risk of death [16].”
BackgroundInfluentialSevere hypocalcaemia because of osteoblastic prostate carcinoma metastases
Yener, S., Demir, Ö., Özdoğan, Ö., Akıncı, B., & Yeşil, S. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01802.x · Cited by 9
Crawford, E. D. (2004) · European Urology Supplements · doi:10.1016/j.eursup.2004.08.007 · Cited by 9
Prostate cancer and markers of bone metabolism: diagnostic, prognostic, and therapeutic implications
Nelson, E. C., Evans, C. P., Pan, C.-X., & Lara, P. N. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0186-3 · Cited by 8
“OC is clearly inferior to other markers [5, 13, 18].”
BackgroundSkeletal Fractures Negatively Correlate With Overall Survival in Men With Prostate Cancer
Oefelein, M. G., RICCHIUTI, V., Conrad, W. G., & Resnick, M. I. (2002) · The Journal of Urology · doi:10.1097/00005392-200209000-00024 · Cited by 8
Current Concepts in the Management of Vertebral Compression Fractures
Mukherjee, S., & Lee, Y.-P. (2011) · Operative Techniques in Orthopaedics · doi:10.1053/j.oto.2011.06.001 · Cited by 7
Bisphosphonate Actions on Bone and Visceral Metastases
Yoneda, T., Hashimoto, N., & Hiraga, T. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-9129-4_10 · Cited by 7
Winquist, E., & Berry, S. R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh234 · Cited by 7
Vinculin: A new target for the diagnosis and treatment of disease
Li, J., Wang, W., Lin, Z., Liu, Z., Zhang, R., Li, R., Zhang, J., Zheng, Y., Qin, D., Wu, Y., et al. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.01.004 · Cited by 6
Exercise interventions for men with prostate cancer
Bourke, L., Smith, D. M., Steed, L., Hooper, R., Catto, J. W. F., Albertsen, P. C., TOMBAL, B. F., Payne, H. A., & Rosario, D. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011251.pub2 · Cited by 6
Tan, S., Wang, Q., Feng, C., Pu, X., Li, D., Jiang, F., Wu, J., Huang, S., Fan, J., Zhong, R., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101573 · Cited by 6
“Bone metastasis is a common complication in the advanced stages of prostate cancer (PCa) [1].”
Li, F., Wang, W., LI, L., Su, D., Chang, Y., GUO, G., He, X., & Li, B. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.1784 · Cited by 6
Optimal bone health management strategies in patients with prostate cancer
Prakash, G. J., & Gautam, G. (2013) · Indian Journal of Urology · doi:10.4103/0970-1591.114024 · Cited by 7
“Clinical manifestation of bone metastases and bone loss 80-90% of men with metastatic castration-resistant PCa (mCRPC) have radiologically detectable bone metastases.[10] Pain is the most common symptom.”
BackgroundThe Molecular Basis of Prostate Carcinogenesis
Dutt, S. S., & Gao, A. C. (2016) · Springer eBooks · doi:10.1007/978-1-59745-458-2_27 · Cited by 6
Sherer, J. T., & Adamus, A. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.2.207 · Cited by 6
Osteoclast-targeted therapy for metastatic prostate cancer
Lee, R. J., & Smith, M. R. (2008) · Therapy · doi:10.2217/14750708.5.1.63 · Cited by 5
Managing metastatic bone disease: Three case studies
Coleman, R. E., Heidenreich, A., & Bell, R. H. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.07.028 · Cited by 5
Second-generation hormonotherapy in prostate cancer and bone microenvironment
Bouleftour, W., Boussoualim, K., Sotton, S., Vassal, C., Thomas, T., Magné, N., & Guillot, A. (2021) · Endocrine Related Cancer · doi:10.1530/erc-21-0118 · Cited by 5
Skeletal complications and the use of bisphosphonates in metastatic prostate cancer
Drudge‐Coates, L. (2006) · International Journal of Palliative Nursing · doi:10.12968/ijpn.2006.12.10.22118 · Cited by 5
Brown, M. W., & Singh, A. K. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.010 · Cited by 5
Oefelein, M. G., RICCHUITI, V., Conrad, W. G., Seftel, A. D., Bodner, D. R., Goldman, H. B., & Resnick, M. (2001) · The Journal of Urology · doi:10.1097/00005392-200111000-00024 · Cited by 5
Body, J. (2006) · Elsevier eBooks · doi:10.1016/b9-78-012088-5/62650-0492 · Cited by 5
Kobayashi, M., Yoshikawa, R., Harada, R., Date, A., Kobayashi, Y., Kozawa, S., & Sakai, Y. (2022) · Progress in Rehabilitation Medicine · doi:10.2490/prm.20220022 · Cited by 4
Redmond, K. M., Turner, P. G., Cole, A., Jain, S., Prise, K. M., & O’Sullivan, J. M. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.110063 · Cited by 4
Physiopathology of cancer metastases in bone and of the changes they induce in bone remodeling
BONUCCI, E. (2002) · RENDICONTI LINCEI · doi:10.1007/bf02904492 · Cited by 5
“5 months (Berruti et al., 2000).”
The role of bisphosphonates in the management of metastatic prostate cancer
Michaelson, M. D., & Smith, M. R. (2003) · Current Oncology Reports · doi:10.1007/s11912-003-0117-4 · Cited by 4
“Biochemical markers of bone resorption are independent predictors of skeletal complications [ 11 ].”
BackgroundProstate cancer and QOL: impact of treatment, disease burden and psychosocial interventions
Penedo, F. J., & Dahn, J. R. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.525 · Cited by 4
Qureshi, A., Shams, U., Akhter, A., & Riaz, S. (2012) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2012.13.9.4369 · Cited by 4
“…pattern of metastatic bone disease which we found was that lung, thyroid and kidney cancer implants in bone are less common and secondary bone involvement by ovarian and gastrointestinal cancers is more common as compared to international data available (Berruti et al., 2000; Yavas et al., 2007).”
BackgroundPain Control with Zoledronic Acid in Patients with Breast Cancer and Metastatic Bone Disease
Nigro, C., Donadio, M., Ardine, M., Beano, A., Mistrangelo, M., Coccorullo, Z., & Bertetto, O. (2004) · American Journal of Cancer · doi:10.2165/00024669-200403040-00005 · Cited by 4
Therapie des hormonrefraktären Prostatakarzinoms
Heidenreich, A. (2005) · Der Urologe · doi:10.1007/s00120-005-0980-8 · Cited by 4
Therapieoptionen des hormonrefraktären Prostatakarzinoms
Heidenreich, A., & Ohlmann, C. (2005) · Der Urologe · doi:10.1007/s00120-005-0928-z · Cited by 4
PREVENTION OF COMPLICATIONS IN CASTRATE-REFRACTORY PROSTATE CANCER PATIENTS WITH BONE METASTASES
Nyushko, K. М., Kalpinskiy, A. S., & Каприн, А. Д. (2015) · Research and Practical Medicine Journal · doi:10.17709/2409-2231-2015-2-3-76-81 · Cited by 3
Meulenbeld, H. J., van Werkhoven, E. D., Coenen, J. L., Creemers, G., Loosveld, O. J. L., Jong, P. C. D., ten Tije, A. J., Fosså, S. D., Polée, M., Gerritsen, W. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.4518 · Cited by 3
“Median [range] 168 [2–8046] 206 [8–11,443] Disease location Bone 95% 97% Node 42% 45% Visceral 16% 18% Measurable disease Measurable 58% 58% Non-measurable 42% 42% Alkaline phosphatase (U/L) Median [range] 195 [40–8130] 201 [45–6045] Albumin (g/L) Median [range] 40 [25–50] 40 [20–50] Baseline PPI 0–1 76% 76% P2 24% 24…”
Exercise interventions for men with prostate cancer
Bourke, L., Smith, D. M., Steed, L., Hooper, R., Catto, J. W. F., Albertsen, P. C., TOMBAL, B. F., Payne, H. A., & Rosario, D. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011251 · Cited by 3
RetractedNg, C. W. Q., Chua, W. M., Lam, W. W.-C., Tong, A. K. T., Ng, D. C. E., Tang, C. Y. L., Tham, W. Y., Kanesvaran, R., Wong, A. S. C., Tay, K. J., et al. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14195 · Cited by 2
“Patients with extensive bone metastases face a poor prognosis and are particularly vulnerable to severe complications, including bone marrow insufficiency, intense pain, fractures, and spinal cord compression [4, 5].”
Update in palliative management of hormone refractory cancer of prostate
Srivastava, A., & Singh, P. (2007) · Indian Journal of Urology · doi:10.4103/0970-1591.30266 · Cited by 2
The use of zoledronic acid in Japanese men with stage D2 prostate cancer
Nakamura, K., Yamada, Y., Rosser, C. J., Arakawa, M., ZENNMAI, K., Kato, Y., Watanabe, M., Katsuda, R., Tobiume, M., Naruse, K., et al. (2009) · Oncology Letters · doi:10.3892/ol_00000002 · Cited by 2
“…with prostate cancer, causing intractable debilitating pain, spinal cord compression, pathologic fractures and abnormalities in serum calcium levels (9). thus, patients with metastatic hormone-refractory prostate cancer (HRPC) are particularly prone to incapacitating progressive bone disease (10).”
Pain Management in Prostate Cancer
Eman, A., Beyaz, S. G., Sağlam, H. S., & Gürcü, M. E. (2012) · Open Journal of Urology · doi:10.4236/oju.2012.223031 · Cited by 2
“3% of prostate cancers with bone metastasis and resistant to hormone and yearly incidence was reported as 12% [9].”
BackgroundMETABOLIC BONE DISEASE INDUCED BY PROSTATE CANCER: RATIONALE FOR THE USE OF BISPHOSPHONATES
Berruti, A., Dogliotti, L., Tucci, M., Tarabuzzi, R., Fontana, D., & Angeli, A. (2001) · The Journal of Urology · doi:10.1097/00005392-200112000-00004 · Cited by 2
Self-citationLevine, A. M., & Aboulafia, A. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-2220-6.10017-9 · Cited by 2
Hormone Therapy for Advanced Prostate Cancer
Hadži-Djokić, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-51712-9_15 · Cited by 3
The contribution of stem cell factor and its receptor c-Kit to cancer-induced bone pain
Contino, K. F., Ollodart, J., Yu, Y., Park, S. H., Tsuzuki, S., Rollins, K., Heethouse, T. M., Chu, J., Steele, L. R., Kimura, T., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.191905 · Cited by 1
Satcher, R. L., Bamidele, O. O., Lin, P. P., Lin, S.-H., Moon, B. S., Hernandez, M., Lewis, V. O., & Chilton, J. A. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.44a004 · Cited by 1
“The formation of skeletal metastasis negatively affects overall survival in patients with prostate cancer, and surgical intervention is considered to be palliative in the majority of these cases [16].”
BackgroundBoccardo, F., Introini, C., Neumaier, C. E., Puppo, P., Ricci, F., Spina, B., Tomasello, L., Scientifiche, S., CARMIGNANI, G., Ciatto, S., et al. (2009) · Cited by 1
Self-citationRadiofrequenzablation: Temperaturverteilung im angrenzenden Gewebe
Bornemann, R., Grötz, S., Pennekamp, P. H., Wilhelm, K., Sander, K., Wirtz, D. C., & Pflugmacher, R. (2017) · TumorDiagnostik & Therapie · doi:10.1055/s-0043-101190 · Cited by 1
“[5] Berutti A, Dogliotti I, Bitossi R et al.”
BackgroundBiochemical Bone Markers in Prostate Cancer Patients with Advanced Bone Metastasis
Al-Saadi, N. H., Al-Daami, N. J. M., & Hussain, J. (2014) · Maǧallaẗ ǧāmiʻaẗ Karbalāʼ/Maǧallaẗ ǧāmiʻaẗ karbalāʼ · Cited by 1
The effect of denosumab administration on bone metabolism for treatment of spinal metastasis
Kawanami, K., Hirasawa, A., & Deie, M. (2021) · Journal of Orthopaedics · doi:10.1016/j.jor.2021.01.009 · Cited by 1
Kojima, S., Masuda, H., Suyama, T., hou, K., Mikami, K., Araki, K., & Naya, Y. (2021) · Prostate Cancer · doi:10.1155/2021/5574067 · Cited by 1
“*e mechanisms of ALP flare have not been fully elucidated, but activation of osteoblasts may be initiated by any cancer pathway by treatment [13, 20, 21].”
BackgroundMetastatic Disease to the Musculoskeletal System
Hicks, D. G. (2008) · Humana Press eBooks · doi:10.1007/978-1-59259-971-4_2 · Cited by 2
“One-third of patients will experience some adverse skeletal manifestation, including vertebral collapse requiring spinal orthosis, spinal cord compression, and pathological bone fracture (12).”
BackgroundUrinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma
Berruti, A., Tucci, M., Dogliotti, L., Scarpa, R. M., & Angeli, A. (2002) · Cancer · doi:10.1002/cncr.10770 · Cited by 1
Self-citationKyphoplasty, Osteoporotic and Traumatic
Lee, Y.-P., & Keller, R. A. (2010) · Springer eBooks · doi:10.1007/978-3-642-03694-1_20
Chapter 85. Treatment and Prevention of Bone Metastases and Myeloma Bone Disease
Body, J. (2008) · Wiley eBooks · doi:10.1002/9780470623992.ch85
Management von Patienten mit Knochenmetastasen in der Praxis - was ist möglich und was ist sinnvoll?
Mesut Remzi, A., & Bachner, M. (2012) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Clinical and Preclinical Treatment Aspects of Castration Resistant Prostate Cancer (CRPC)
Meulenbeld, H. J. (2012) · EUR Research Repository (Erasmus University Rotterdam)
Skeletal Related Events in Prostate Cancer: Important Therapeutic Considerations
Alvarez, M., Gómez, J. M. F., Jalon, A., Vázquez, V. B., Miguelez, E., & Valle, F. (2011) · InTech eBooks · doi:10.5772/25560
Premature conclusions may harm good ideas
Staudenherz, A., & Sinzinger, H. F. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1753-0
Hong, S., You, D., Jeong, I. G., Hong, J. H., Ahn, H., & Kim, C. (2009) · Korean journal of urology · doi:10.4111/kju.2009.50.12.1174
“전이성 척수압박 (metastatic spinal cord compression; MSCC) 은 전립선암 환자의 1-12%에서 발생하며 [1], 척추뼈 전이 가 발생한 환자 중에서 6%에서 발생하여 다른 합병증에 비 해서 빠른 치료를 요하는 응급상황이다 [2].”
김응찬, Kim, K.-H., Park, C.-S., Lee, S.-Y., 유흥준, 조재환, 장현철, 김보희, & 한만석 (2011) · Journal of the Korean Society of Radiology · doi:10.7742/jksr.2011.5.1.037
“전이성 척추암은 전립선암환자의 1-12%에서 발생하며 ([5]), 척추뼈 전이가 발생한 환자 중에서 6%에서 발생하 여 다른 합병증에 비해서 빠른 치료를 요하는 응급상 황이다([6]).”
BackgroundThe usefulness of MR subtraction technique in metastatic spinal cancer
Cho, J.-H., Lee, H.-K., Han, B.-J., Lee, J., Dong, K.-R., Chung, W.-K., & Bae, J.-Y. (2013) · The Imaging Science Journal · doi:10.1179/1743131x12y.0000000005
Cho, J.-H., Lee, H.-K., Kim, Y. K., Dong, K.-R., Chung, W.-K., & Joo, K.-J. (2013) · Journal of the Korean Physical Society · doi:10.3938/jkps.62.700
Seguridad del ácido zoledrómico en el control del dolor en el estadio M1b del cáncer de próstata
Álvarez-Múgica, M., Gómez, J. M. F., Monzón, A. J., Álvarez, R. C. G., Rodríguez, J. G., & Benito, J. (2007) · Actas Urológicas Españolas · doi:10.1016/s0210-4806(07)73771-3
Knochenmetastasen bei urologischen Malignomen
Todenhöfer, T., & Stenzl, A. (2014) · Springer eBooks · doi:10.1007/978-3-662-43471-0_14
PathologicalSproutingofAdultNociceptorsinChronic ProstateCancer-InducedBonePain
Bloom, A. P., Stake, J., Mantyh, W. G., & Taylor, R. N. (2010)
Lipton, A. (2010) · Oncology Times · doi:10.1097/01.cot.0000388033.23565.f8
Corral-Gudino, L. (2015) · Exposure and Health · doi:10.1007/978-94-007-7745-3_2-1
Radium-223 in the Modern Treatment of Metastatic Castration-resistant Prostate Cancer
Головко, С. В. (2021) · Health of Man · doi:10.30841/2307-5090.4.2020.225652
(2001) · The Prostate Journal · doi:10.1046/j.1525-1411.2001.32010.x
Corral-Gudino, L. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_2
Metadata
- Authors
- BERRUTI, A., DOGLIOTTI, L., BITOSSI, R., FASOLIS, G., GORZEGNO, G., BELLINA, M., TORTA, M., PORPIGLIA, F., FONTANA, D., & ANGELI, A.
- Affiliations
- Ospedale San Luigi Gonzaga (IT)
- Venue
- Journal of Urology
- Published
- 2000-10
- Volume
- 164
- Issue
- 4
- Pages
- 1248-1253
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2159622173
- Cited by
- 212
- References
- 33
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 2 · 2016: 6 · 2015: 8 · 2014: 9 · 2013: 8 · 2012: 10
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Journal of Urology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- skeletal complications, bone metastatic prostate cancer, castration-resistant prostate cancer, bone turnover markers, urinary deoxypyridinoline, bone resorption, bone formation, pathological fracture, spinal cord compression, vertebral collapse, alkaline phosphatase, predictive biomarkers, bone pain
- MeSH terms
- Aged, Aged, 80 and over, Alkaline Phosphatase, Amino Acids, Bone Neoplasms, Bone Resorption, Calcium, Evaluation Studies as Topic, Humans, Male, Middle Aged, Prostatic Neoplasms, Regression Analysis, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.